Literature DB >> 528568

Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma.

P J Frosch, B M Czarnetzki, E Macher, E Grundmann, I Gottschalk.   

Abstract

A 55-year-old white woman received chemotherapy with DTIC after surgery for malignant melanoma (stage I, SSM IV, depth of invasion 12 mm). She died suddenly during the second treatment cycle. Autopsy revealed massive necrosis of the liver and thrombosis of the hepatic veins. The cause of the fatal outcome is attributed to the adverse toxic effects of DTIC.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 528568     DOI： 10.1007/BF00410649

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  10 in total

1.  Mechanism of action and pharmacology studies with DTIC (NSC-45388).

Authors:  T L Loo; G E Housholder; A H Gerulath; P H Saunders; D Farquhar
Journal:  Cancer Treat Rep       Date:  1976-02

2.  Hepatic-vein thrombosis after chemotherapy for histiocytoma.

Authors:  L M Lehrner; R E Enck
Journal:  Ann Intern Med       Date:  1978-04       Impact factor: 25.391

Review 3.  Chemotherapy of malignant melanoma.

Authors:  J K Luce
Journal:  Cancer       Date:  1972-12       Impact factor: 6.860

4.  Combination phase 1-II study of imidazole carboxamide (NCS45388).

Authors:  D E Wagner; G Ramirez; A J Weiss; G Hill
Journal:  Oncology       Date:  1972       Impact factor: 2.935

5.  N-demethylation the antineoplastic agent4(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide by rats and man.

Authors:  J L Skibba; D D Beal; G Ramirez; G T Bryan
Journal:  Cancer Res       Date:  1970-01       Impact factor: 12.701

6.  Photodegradation of dacarbazine.

Authors:  G M Baird; M L Willoughby
Journal:  Lancet       Date:  1978-09-23       Impact factor: 79.321

7.  Studies of the mechanism of action of the antitumor agent 5(4)-(3,3-dimethyl-1-triazeno) imidazole-4(5)-carboxamide in Bacillus subtilis.

Authors:  P P Saunders; G A Schultz
Journal:  Biochem Pharmacol       Date:  1970-03       Impact factor: 5.858

8.  Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.

Authors:  R O Johnson; G Metter; W Wilson; G Hill; E Krementz
Journal:  Cancer Treat Rep       Date:  1976-02

9.  Results with methyl-CCNU and DTIC in metastatic melanoma.

Authors:  M E Costanza; L Nathanson; D Schoenfeld; J Wolter; J Colsky; W Regelson; T Cunningham; N Sedransk
Journal:  Cancer       Date:  1977-09       Impact factor: 6.860

10.  Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases.

Authors:  P F Griner; A Elbadawi; C H Packman
Journal:  Ann Intern Med       Date:  1976-11       Impact factor: 25.391
  10 in total
  11 in total

Review 1.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 2.  Clinical management of cytotoxic drug overdose.

Authors:  L L Thomas; M J Mertens; A E von dem Borne; C J van Boxtel; C H Veenhof; E P Veies
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Jul-Aug

3.  DTIC (dacarbazine)-induced hepatic damage. Possible pathogenesis and prevention.

Authors:  B M Czarnetzki; E Macher
Journal:  Arch Dermatol Res       Date:  1981       Impact factor: 3.017

Review 4.  How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma.

Authors:  J Wolchok
Journal:  Ann Oncol       Date:  2012-09       Impact factor: 32.976

5.  A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors.

Authors:  D R Adkins; R Irvin; J Kuhn; D H Boldt; G D Roodman; D Salzman; C Freytes; D D Von Hoff; C F LeMaistre
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

6.  [Veno-occlusive syndrome with acute liver dystrophy following decarbazine therapy of malignant melanoma (author's transl)].

Authors:  H Voigt; J Caselitz; M Jänner
Journal:  Klin Wochenschr       Date:  1981-03-02

Review 7.  Drug effects on the liver. An updated tabular compilation of drugs and drug-related hepatic diseases.

Authors:  J Ludwig; R Axelsen
Journal:  Dig Dis Sci       Date:  1983-07       Impact factor: 3.199

8.  A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma.

Authors:  Juliane Schelhorn; Heike Richly; Marcus Ruhlmann; Thomas C Lauenstein; Jens M Theysohn
Journal:  Acta Radiol Open       Date:  2015-04-06

9.  Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.

Authors:  N Yamazaki; H Uhara; S Fukushima; H Uchi; N Shibagaki; Y Kiyohara; A Tsutsumida; K Namikawa; R Okuyama; Y Otsuka; T Tokudome
Journal:  Cancer Chemother Pharmacol       Date:  2015-09-25       Impact factor: 3.333

Review 10.  Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.

Authors:  Jedd D Wolchok; F Stephen Hodi; Jeffrey S Weber; James P Allison; Walter J Urba; Caroline Robert; Steven J O'Day; Axel Hoos; Rachel Humphrey; David M Berman; Nils Lonberg; Alan J Korman
Journal:  Ann N Y Acad Sci       Date:  2013-06-17       Impact factor: 5.691
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.